HOME >> MEDICINE >> NEWS
Experimental pill found to improve symptoms in patients with non-small-cell lung cancer

ORLANDO, FLA. (May 19, 2002, 12:00 p.m., EST) An experimental pill has been found to improve symptoms and quality of life in patients with non-small-cell lung cancer, according to research findings presented by Ronald B. Natale, M.D., Acting Medical Director at Cedars-Sinai Comprehensive Cancer Center, and lead author of the study. The pill, called ZD 1839 (Iressa) is one of a new class of drugs that targets and blocks a key growth signal in cancer cells.

The study, presented at the 38th annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, evaluated 216 patients with recurrent non-small-cell lung cancer who had undergone two or more rounds of chemotherapy. One group of patients received 250 mg of ZD 1839 (Iressa) daily, while the second group received ZD 1839 at 500 mg each day until the disease progressed. The investigators found that lung cancer symptoms, such as cough, shortness of breath, chest pain or tightness, appetite and fatigue, were greatly improved in about 40 percent of patients. Further, they found that symptom improvement was associated with a longer survival.

Our results show that patients who felt better after taking ZD 1839, actually lived longer than those whose symptoms did not improve, said Dr. Natale. This is important because it shows that a daily pill reduced symptoms such to the extent that many of our patients were able to resume their normal activities and enjoy life for longer.

ZD 1839 (Iressa), a pill developed by AstraZeneca, has been found to work in both laboratory and clinical trials by targeting and blocking a key growth signaling mechanism in cancer cells called the epidermal growth factor receptor (EGFR). Otherwise known as HER1, the EGFR is a part of the HER kinase family of proteins that control cell growth and can stimulate the spread of cancer when over-expressed on malignant cells.

Non-small-cell lung cancer is the most common type of lung cancer,
'"/>

Contact: Kelli Stauning
kelli.stauning@cshs.org
310-423-3674
Cedars-Sinai Medical Center
19-May-2002


Page: 1 2 3

Related medicine news :

1. St. Jude scientist wins International Society of Experimental Hematology award
2. Experimental drug improves sleep in older patients, Wake Forest Baptist study shows
3. Experimental drug used to treat recurrent ovarian cancer shows promising results
4. Experimental treatment yields new hope for children battling cerebral palsy
5. Experimental drugs show promise in halting brain tumors
6. Experimental drugs reduce neuron death in rats following insulin shock
7. Experimental drug reverses effects of Fabry disease in mice
8. Experimental peptides prevent diabetes and halt its progression
9. Experimental testosterone patch shows promise for treating diminished sexual function in surgically menopausal women
10. Clinical Trial Demonstrates Experimental Growth Factor Increases Eligibility For Autologous Stem Cell Transplantation
11. Acupuncture found to lower elevations in blood pressure

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
Cached News: